Merkel Cell Carcinoma
Symptoms, Doctors, Treatments, Advances & More

Merkel Cell Carcinoma Overview

Save information for later
Sign Up

Learn About Merkel Cell Carcinoma

What is the definition of Merkel Cell Carcinoma?
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer. It usually develops as a single, painless, bump on sun-exposed skin. The bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. It may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. Factors associated with developing MCC include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the Merkel cell polyomavirus. The Merkel cell polyomavirus has been detected in most people who have MCC.
What are the alternative names for Merkel Cell Carcinoma?
  • Merkel cell carcinoma
  • Carcinoma, merkel cell
  • Cutaneous neuroendocrine carcinoma
  • Merkel cell cancer
  • Merkle tumors
Who are the top Merkel Cell Carcinoma Local Doctors?
Paul Nghiem
Elite in Merkel Cell Carcinoma
Dr. Paul Nghiem
Dermatology
Elite in Merkel Cell Carcinoma
Dr. Paul Nghiem
Dermatology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
855-557-0555
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Nghiem is a Dermatologist in Seattle, Washington. Dr. Nghiem is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Merkel Cell Carcinoma, Squamous Cell Skin Carcinoma, Eccrine Porocarcinoma, and Melanoma.

Manisha Thakuria
Elite in Merkel Cell Carcinoma
Dr. Manisha Thakuria
Dermatology
Elite in Merkel Cell Carcinoma
Dr. Manisha Thakuria
Dermatology

Brigham And Women's Hospital, Phototherapy Center

221 Longwood Avenue Suite RF-156 Brigham And Women's At 221 Longwood Boston, Suite RF-156 Brigham And Women's At 221 Longwood, 
Boston, MA 
617-732-9080
Languages Spoken:
English
See accepted insurances

Manisha Thakuria is a Dermatologist in Boston, Massachusetts. Dr. Thakuria is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Merkel Cell Carcinoma, Actinic Keratosis, Warts, and Granuloma Annulare.

 
 
 
 
Learn about our expert tiers
Learn More
Kelly G. Paulson
Elite in Merkel Cell Carcinoma
Dr. Kelly G. Paulson
Oncology | Hematology
Elite in Merkel Cell Carcinoma
Dr. Kelly G. Paulson
Oncology | Hematology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
206-386-3751
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kelly Paulson is a Hematologist and an Oncologist in Seattle, Washington. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. Her top areas of expertise are Merkel Cell Carcinoma, Neuroendocrine Tumor, Small Cell Lung Cancer (SCLC), and Colorectal Cancer. Dr. Paulson is currently accepting new patients.

View All Doctors
What are the latest Merkel Cell Carcinoma Clinical Trials?
A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatmen...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers
A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Drug
Study Phase: Phase 1/Phase 2

Summary: This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune syst...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center